Leading global professional services firm Alvarez & Marsal (A&M) has expanded its life sciences, biopharmaceutical and medical technology (MedTech) offerings with the appointment of Philadelphia-based Steve Moscoe as a Managing Director in its Healthcare Industry Group. Mr. Moscoe’s hire extends A&M’s breadth of services and reflects the firm’s commitment to advise biopharmaceutical, medical device, and broader life sciences clients navigate complex market challenges.
Mr. Moscoe brings more than 30 years of life sciences industry and consulting experience to A&M. He helps pharmaceutical and biotechnology organizations solve for manufacturing, network development, supply chain, and other operations and finance process challenges. His ability to develop and execute customized solutions is complemented by his expertise in the small molecule, biologics, and medical device/diagnostics sectors.
“We continue to grow and expand our pharmaceutical and life sciences practice. Steve’s addition to our team recognizes the importance of the cell & gene therapy sector’s impact on the life science and healthcare industry and provides further opportunity to service our clients. Steve’s expertise enhances our offering and strengthens our ability to help pre-commercial and commercial clients maximize value,” said Peter Urbanowicz, Managing Director and Co-Head of A&M’s Healthcare Industry Group. “Steve’s results-oriented mindset and ability to translate complex business requirements into actionable solutions aligns with A&M’s operational heritage.”
Most recently, Mr. Moscoe has focused on cell and gene therapies and biologic products, including those paired with complex small molecules. He has also helped organizations build their internal manufacturing capabilities, as well as develop robust contract manufacturing and vendor global networks to support multifaceted supply chain and regulatory requirements.
Mr. Moscoe has considerable experience with autologous therapies and personalized medicine, as well as supporting unique client needs resulting from a patient-centered supply chain. Additionally, he has helped direct clients’ transition from early clinical to commercialization, usually at the Clinical Trial Phase II/III inflection points.
“Steve’s pragmatic approach to operational improvements along with supply chain and digital transformation has helped pharmaceutical organizations, across multiple value chains, drive growth and achieve efficiency,” said Martin McGahan, Managing Director and Co-Head of A&M’s Healthcare Industry Group. “His in-depth industry experience spans providers, payers, life sciences, and service organizations, and aligns with the Healthcare Industry Group’s core capabilities. His knowledge of traditional and emerging therapies alongside his operational know-how will benefit clients seeking to drive change.”
Mr. Moscoe joins A&M from Point B, where he helped build the life sciences practice through customer engagement, growth investments, intellectual capital development, and delivery excellence. Previously, he served in roles at GE, CIGNA, and Merck (MSD), focusing on finance, operations, and systems management. He has also led client engagements at PwC and several mid-sized consulting firms, focusing on finance and operations capabilities in the manufacturing, healthcare, and life sciences industries.
Mr. Moscoe is an active member of several life sciences focused organizations, including Life Sciences PA. He earned a master’s degree in International Business/Finance at the University of South Carolina Moore School of Business and a bachelor’s degree in Finance/Management at the University of Kentucky.
Sourced from Alvarez & Marsal